Evidence-based Complementary and Alternative Medicine : eCAM · 9 authors, 6 centres
This summary was generated by AI from a single paper. It has not been reviewed by a clinician and is not clinical advice. Verify against the source before acting on it.
This randomized crossover pilot study in 10 healthy adults compared the blood concentrations of a novel quercetin formulation (LipoMicel) to standard quercetin. The LipoMicel formulation significantly increased quercetin absorption by up to 15-fold compared to the standard form.
This pilot study evaluated the pharmacokinetics of different quercetin formulations in 10 healthy adults using a diet-controlled, crossover design. In a single-dose phase, participants received standard quercetin or LipoMicel at 250, 500, or 1000 mg, and blood was monitored for 24 hours. LipoMicel significantly increased quercetin absorption; at the same 500 mg dose, it achieved a 7-fold higher AUC0–24 compared to standard quercetin (p < 0.001). A 1000 mg LipoMicel dose resulted in a 15-fold higher AUC than standard 500 mg quercetin (p < 0.001). In a multiple-dose phase, LipoMicel sustained blood concentrations over 72 hours. The study also identified major circulating metabolites as methylated, sulfate, and glutathione conjugates. Limitations include the small sample size, inter-individual variability, and the lack of a complete 24-hour profile in the multiple-dose phase. The findings suggest LipoMicel enhances quercetin bioavailability, but larger studies are needed to confirm these results.
